Current consensus from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends combination therapy for patients with HbA1c levels exceeding 8.5%, and insulin based therapy when HbA1c levels above 10% [4]. This evidence concerns the gene INS and diabetes mellitus.